KR20120100703A - 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 - Google Patents

바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 Download PDF

Info

Publication number
KR20120100703A
KR20120100703A KR1020117026088A KR20117026088A KR20120100703A KR 20120100703 A KR20120100703 A KR 20120100703A KR 1020117026088 A KR1020117026088 A KR 1020117026088A KR 20117026088 A KR20117026088 A KR 20117026088A KR 20120100703 A KR20120100703 A KR 20120100703A
Authority
KR
South Korea
Prior art keywords
cytokine
cancer
lif
cell proliferation
glioma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117026088A
Other languages
English (en)
Korean (ko)
Inventor
후안 세오안 수아레즈
실비아 페누엘라스 프리에토
호세 바셀가 토레스
Original Assignee
펀다시오 프리바다 인스티튜시오 카탈라나 디 레세르카 아이 에스투디스 아반카츠
펀다시오 프리바다 인스티튜트 디 레세르카 호스피탈 유니버시타리 발 헤브론
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 디 발 헤브론
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다시오 프리바다 인스티튜시오 카탈라나 디 레세르카 아이 에스투디스 아반카츠, 펀다시오 프리바다 인스티튜트 디 레세르카 호스피탈 유니버시타리 발 헤브론, 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 디 발 헤브론 filed Critical 펀다시오 프리바다 인스티튜시오 카탈라나 디 레세르카 아이 에스투디스 아반카츠
Publication of KR20120100703A publication Critical patent/KR20120100703A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
KR1020117026088A 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 Ceased KR20120100703A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ESP200900928 2009-04-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030504A Division KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Publications (1)

Publication Number Publication Date
KR20120100703A true KR20120100703A (ko) 2012-09-12

Family

ID=42342718

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020117026088A Ceased KR20120100703A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020197022597A Ceased KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020227007752A Ceased KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020207017470A Active KR102373754B1 (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020187018827A Ceased KR20180079470A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020177030504A Ceased KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020197022597A Ceased KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020227007752A Ceased KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020207017470A Active KR102373754B1 (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020187018827A Ceased KR20180079470A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020177030504A Ceased KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Country Status (24)

Country Link
US (4) US10100112B2 (https=)
EP (2) EP2414394A2 (https=)
JP (5) JP6207836B2 (https=)
KR (6) KR20120100703A (https=)
CN (2) CN107964043A (https=)
AU (1) AU2010233791B2 (https=)
BR (1) BRPI1015369A2 (https=)
CA (1) CA2757680C (https=)
CY (1) CY1124148T1 (https=)
DK (1) DK3045474T3 (https=)
EA (1) EA201101450A1 (https=)
ES (2) ES2363358B1 (https=)
HR (1) HRP20210352T1 (https=)
HU (1) HUE054196T2 (https=)
IL (1) IL215467A (https=)
LT (1) LT3045474T (https=)
MX (1) MX336903B (https=)
PL (1) PL3045474T3 (https=)
PT (1) PT3045474T (https=)
SG (2) SG10202010568RA (https=)
SI (1) SI3045474T1 (https=)
SM (1) SMT202100153T1 (https=)
WO (1) WO2010115868A2 (https=)
ZA (1) ZA201107215B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101338533B1 (ko) * 2005-07-19 2013-12-12 스템젠 에스.피.에이. Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
EP3116867A4 (en) * 2014-03-11 2017-10-18 Godavari Biorefineries Ltd. Cancer stem cell targeting compounds
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
MX385372B (es) 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
AU2017381585B2 (en) 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
CN112703202A (zh) * 2018-06-18 2021-04-23 免疫医疗有限公司 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法
AU2019291307B2 (en) * 2018-06-18 2024-04-04 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
EP3957324A4 (en) * 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
CN120507517B (zh) * 2025-05-21 2026-04-10 浙江省肿瘤医院 用于评估宫颈癌鳞癌和腺癌特异性的预后分子标记物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CN102137939A (zh) * 2008-08-29 2011-07-27 霍夫曼-拉罗奇有限公司 不依赖vegf的肿瘤的诊断和治疗
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
ES2363358A1 (es) 2011-08-01
JP2022031742A (ja) 2022-02-22
KR20200078668A (ko) 2020-07-01
EP3045474A3 (en) 2016-09-28
IL215467A0 (en) 2011-12-29
EP2414394A2 (en) 2012-02-08
PL3045474T3 (pl) 2021-08-09
CN107964043A (zh) 2018-04-27
CA2757680C (en) 2021-11-02
US20190211095A1 (en) 2019-07-11
AU2010233791A1 (en) 2011-11-03
DK3045474T3 (da) 2021-03-22
MX336903B (es) 2016-02-04
CA2757680A1 (en) 2010-10-14
JP7197665B2 (ja) 2022-12-27
JP2016040255A (ja) 2016-03-24
JP6207836B2 (ja) 2017-10-04
JP2020090522A (ja) 2020-06-11
US20200385455A1 (en) 2020-12-10
EA201101450A1 (ru) 2012-04-30
WO2010115868A3 (en) 2011-02-03
JP2012522756A (ja) 2012-09-27
SMT202100153T1 (it) 2021-05-07
PT3045474T (pt) 2021-03-22
US11999782B2 (en) 2024-06-04
KR102373754B1 (ko) 2022-03-15
CN102574918A (zh) 2012-07-11
ES2363358B1 (es) 2012-06-21
SG10202010568RA (en) 2020-11-27
KR20190093691A (ko) 2019-08-09
US10100112B2 (en) 2018-10-16
EP3045474A2 (en) 2016-07-20
US20240400667A1 (en) 2024-12-05
HRP20210352T1 (hr) 2021-05-28
EP3045474B1 (en) 2021-01-13
ES2864639T3 (es) 2021-10-14
ZA201107215B (en) 2012-12-27
KR20180079470A (ko) 2018-07-10
LT3045474T (lt) 2021-05-10
AU2010233791B2 (en) 2016-01-21
KR20170121319A (ko) 2017-11-01
WO2010115868A2 (en) 2010-10-14
BRPI1015369A2 (pt) 2021-06-29
JP2019006784A (ja) 2019-01-17
CY1124148T1 (el) 2022-05-27
IL215467A (en) 2016-06-30
HUE054196T2 (hu) 2021-08-30
KR20220035978A (ko) 2022-03-22
MX2011010425A (es) 2012-03-06
SG175032A1 (en) 2011-11-28
US20120114671A1 (en) 2012-05-10
SI3045474T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
US20240400667A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150406

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160816

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160816

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170327

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161116

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150406

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170721

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170626

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170327

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161116

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160816

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150406

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171023